Download PDF
Thromb Haemost 1992; 67(05): 537-541
DOI: 10.1055/s-0038-1648489
Original Articles
Schattauer GmbH Stuttgart

Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor

Lars C Petersen
Novo Nordisk Research Institute, Novo Nordisk A/S, Denmark
,
Søren E Bjørn
Novo Nordisk Research Institute, Novo Nordisk A/S, Denmark
,
Ole Nordfang
Novo Nordisk Research Institute, Novo Nordisk A/S, Denmark
› Author Affiliations
Further Information

Publication History

Received 21 August 1991

Accepted after revision 20 November 1991

Publication Date:
03 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The effect of human neutrophil elastase and cathepsin G on recombinant tissue factor pathway inhibitor (TFPI) was investigated. A weak inhibition by TFPI of both elastase (Kx = 0.4 μM) and cathepsin G (Kx = 0.1 μM) was observed. Neutrophil elastase rapidly cleaved TFPI at the Thr87-Thr88 bond situated at the link between Kunitz domains I and II. Cleavage of TFPI by cathepsin G was also observed, but the reaction was much slower and resulted in a number of fragments. Proteolytic cleavage by both elastase and cathepsin G resulted in destruction of inhibitor function with respect to TFPI’s inhibition of factor Xa. Cleavage by neutrophil elastase was capable of restoring factor Xa amidoly-tic activity after its initial inhibition by TFPI. Inhibition of cathepsin G by TFPI was strongly augmented by stoichiometric amounts of factor Xa. However, the augmentation was temporary, presumably due to concomitant cleavage of TFPI by cathepsin G. These observations may have implications for the putative effect of neutrophil leukocyte stimulation on the regulation of the tissue factor-mediated coagulation pathway. Conversely, formation of a factor Xa/TFPI complex may reduce or modulate the proteolytic potential of stimulated leukocytes by temporary inhibition of cathepsin G.

 

  • References

  • 1 Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 11-16
    PubMedGoogle Scholar
  • 2 Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases: a critical role of kallikein. J Exp Med 1973; 138: 1564-1583
    CrossrefPubMedGoogle Scholar
  • 3 Rosenberg J, Beeler D, Rosenberg RD. Activation of human prothrombin by highly purified human factors V and Xa in the presence of human antithrombin. J Biol Chem 1975; 250: 1607-1617
    PubMedGoogle Scholar
  • 4 Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor Vila activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204-212
    PubMedGoogle Scholar
  • 5 Broze GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-156
    PubMedGoogle Scholar
  • 6 Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651
    PubMedGoogle Scholar
  • 7 Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546
    CrossrefPubMedGoogle Scholar
  • 8 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004
    PubMedGoogle Scholar
  • 9 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520
    CrossrefPubMedGoogle Scholar
  • 10 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376
    CrossrefPubMedGoogle Scholar
  • 11 Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon PC, Fournel MA. Inactivation of human anti thrombin by neutrophil elastase: kinetics of the heparin-dependent reaction. J Biol Chem 1989; 264: 10493-10500
    PubMedGoogle Scholar
  • 12 Kondo S, Kisiel W. Evidence that plasma lipoproteins inhibit the factor Vlla-tissue factor complex by a different mechanism than extrinsic pathway inhibitor. Blood 1989; 70: 1947-1954
    PubMedGoogle Scholar
  • 13 Thim L, Bjoern SE, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, Hedner U. Amino acid sequence and posttranslational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793
    CrossrefPubMedGoogle Scholar
  • 14 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor: production, isolation and characterization of its inhibitory activity on tissue factor-initiated reactions. J Biol Chem 1990; 265: 16786-16793
    PubMedGoogle Scholar
  • 15 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400
    CrossrefPubMedGoogle Scholar
  • 16 Day KC, Hoffmann LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 78: 1538-1545
    PubMedGoogle Scholar
  • 17 Nordfang O, Valentin S, Bech TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemostas 1991; 66: 464-467
    PubMedGoogle Scholar
  • 18 Nordfang O, Bjprn S, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminal of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-10376
    CrossrefPubMedGoogle Scholar
  • 19 Baugh RJ, Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry 1976; 15: 836-843
    CrossrefPubMedGoogle Scholar
  • 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 21 Thim L, Hansen MT, Soerensen AR. Secretion of human insulin by a transformed yeast cell. FEBS Lett 1987; 212: 307-312
    CrossrefPubMedGoogle Scholar
  • 22 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor VH-tissue factor complex also inhibits Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343
    PubMedGoogle Scholar
  • 23 Schmidt W, Egbring R, Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thromb Res 1975; 6: 315-326
    CrossrefPubMedGoogle Scholar
  • 24 Henry RL. Leucocytes and thrombosis. Thromb Diath Haemorrh 1965; 13: 35-46
    PubMedGoogle Scholar
  • 25 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709
    CrossrefPubMedGoogle Scholar
  • 26 Brower MS, Harpel P. Proteolytic cleavage and inactivation of a2 -plasmin inhibitor and Cl inactivator by human polymorphonuclear leucocyte elastase. J Biol Chem 1982; 257: 9849-9854
    PubMedGoogle Scholar
  • 27 Abrahamson M, Mason RW, Hansson H, Buttle DJ, Grubb A, Ohlsson K. Human cystatin C: role of the N-terminal segment in the inhibition of human systeine proteinases and in its inactivation by leukocyte elastase. Biochem J 1991; 273: 621-626
    CrossrefPubMedGoogle Scholar
  • 28 Potempa J, Kwon K, Chawla R, Travis J. Inter-a-trypsin inhibitor: inhibition spectrum of native and derived forms. J Biol Chem 1989; 264: 15109-15114
    PubMedGoogle Scholar
  • 29 Broze GJ. LACI. Thromb Haemostas 1991; 65: 691 (Abstr)
    PubMedGoogle Scholar
  • 30 Machovich R, Owen WG. The elastase-mediated pathway of fibrinolysis. Blood Coag Fib 1990; 1: 79-90
    PubMedGoogle Scholar